Guidelines to Diagnosis and Monitoring of Fabry Disease and Review of Treatment Experiences

Journal of Pediatrics

Volumn 155, Issue 4 SUPPL., 2009, Pages

  Martins, Ana Maria ^a   D'Almeida, Vânia ^a   Kyosen, Sandra Obikawa ^a   Takata, Edna Tiemi ^a   Delgado, Alvimar Gonçalves ^b   Barbosa Ferreira Gonçalves, Ângela Maria ^c   Benetti Filho, Caio César ^d   Filho, Dino Martini ^e   Biagini, Gilson ^f   Pimentel, Helena ^g   Abensur, Hugo ^h   Guimarães, Humberto Cenci ⁱ   Gomes, Jaelson Guilhem ^j   Neto, José Sobral ^k   Dias D'Almeida, Luiz Octávio ^l   Carvalho, Luiz Roberto ^m   Harouche, Maria Beatriz ⁿ   Jacometti Maldonado, Maria Cristina ^o   Nascimento, Osvaldo J M ⁿ   dos Santos Montoril, Paulo Sergio ^p   Bastos, Ricardo Villela ^q   more..

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Clínica de Dermatologia do Hospital   (Brazil)

^d Unureste Presidente Prudente   (Brazil)

^e HOSPITAL BENEFICÊNCIA PORTUGUESA DE SÃO PAULO   (Brazil)

^f Hospital São Lucas de Curitiba   (Brazil)

^g Associacao de Pais e Amigos dos Excepcionais de Sao Paulo   (Brazil)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ Clínica Censi Guimarães   (Brazil)

^j Instituto de Hemodiálise de Sorocaba   (Brazil)

^k CentroCard   (Brazil)

^l Hospital Regional Araruama   (Brazil)

^m Hospital do Trauma   (Brazil)

ⁿ FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^o PAM Heliopolis   (Brazil)

^p Centrocor   (Brazil)

^q FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AGALSIDASE BETA; ALPHA GALACTOSIDASE; AMITRIPTYLINE; CARBAMAZEPINE; DNA; EYE DROPS; GABAPENTIN; GLOBOTRIAOSYLCERAMIDE; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; PHENYTOIN;

ARTICLE; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CELL FUNCTION; CENTRAL NERVOUS SYSTEM DISEASE; CHILDHOOD DISEASE; CHILL; CRANIAL NERVE; CRYOTHERAPY; DELAYED DIAGNOSIS; DNA DETERMINATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENZYME REPLACEMENT; EYE DISEASE; FABRY DISEASE; FEVER; FILTER; GASTROINTESTINAL SYMPTOM; GENE LOCATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETICS; GLOMERULUS FILTRATION RATE; HEMANGIOKERATOMA; HEMIZYGOSITY; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTORY; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOCYTE; LUNG DISEASE; NERVE CELL; NERVE FIBER; NERVE INJURY; NEUROPATHIC PAIN; PARESTHESIA; PATHOLOGY; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RHEUMATIC DISEASE; SEROCONVERSION; SEX DIFFERENCE; SKIN MANIFESTATION; SOCIAL PSYCHOLOGY; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; X CHROMOSOME LINKED DISORDER;

ADULT; AGE FACTORS; ALPHA-GALACTOSIDASE; BRAZIL; COHORT STUDIES; FABRY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; SEX FACTORS; TREATMENT OUTCOME;

EID: 70349187343     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2009.07.003     Document Type: Article

References (128)

1. Desnick R., Ioannou Y., and Eng C. Alpha-Galactosidase A deficiency: Fabry disease. In: Scriver CR B.A., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease. 8th ed (2001), McGraw-Hill, New York, NY 3733-3774
2. Deegan P.B., and Baehner A.F. Barba Romero MA, Hughes DA, Kampmann C, Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 43 (2006) 347-352
3. Wang R.Y., Lelis A., Mirocha J., and Wilcox W.R. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9 (2007) 34-45
4. Wilcox W.R., Oliveira J.P., Hopkin R.J., Ortiz A., Banikazemi M., Feldt-Rasmussen U., et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93 (2008) 112-128
5. Nakao S., Kodama C., Takenaka T., Tanaka A., Yasumoto Y., Yoshida A., et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 64 (2003) 801-807
6. Meikle P.J., Hopwood J.J., Clague A.E., and Carey W.F. Prevalence of lysosomal storage disorders. JAMA 281 (1999) 249-254
7. Anderson W. A case of "angiokeratoma". Br J Dermatol 10 (1898) 113-117
8. Fabry J. Ein Beitrag zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch Dermatol Syphilis 43 (1898) 187-200
9. Pompen A., Ruiter M., and Wyers H. Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease: two autopsy reports. Acta Med Scand 128 (1947) 234-255
10. Scriba K. Zur Diagnostik des Angiokeratoma corporis diffusum Fabry mit cardio-vasorenalem Symptomenkomplex. Verh Dtsch Ges Pathol 34 (1950) 221
11. Hornbostel H., and Scriba K. Zur Diagnostik des Angiokeratoma corporis diffusum Fabry mit cardio-vasorenalem Symptomenkomplex als posphatidspeicherungskrankheit durch Probeexcision der Haut. Klin Wochenschr 31 (1953) 68
12. Sweeley C., and Klionsky B. Fabry's disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 238 (1963) 3148-3150
13. Hers H. Inborn lysosomal diseases. Gastroenterology 48 (1965) 625-633
14. Brady R.O. Enzymatic abnormalities in diseases of sphingolipid metabolism. Clin Chem 13 (1967) 565-577
15. Brady R.O., Tallman J.F., Johnson W.G., Gal A.E., Leahy W.R., Quirk J.M., et al. Replacement therapy for inherited enzyme deficiency: use of purified ceramidetrihexosidase in Fabry's disease. N Engl J Med 289 (1973) 9-14
16. Desnick R.J., Dean K.J., Grabowski G., Bishop D.F., and Sweeley C.C. Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes. Proc Natl Acad Sci U S A 76 (1979) 5326-5330
17. Mapes C.A., Anderson R.L., Sweeley C.C., Desnick R.J., and Krivit W. Enzyme replacement in Fabry's disease, an inborn error of metabolism. Science 169 (1970) 987-989
18. Dingermann T. Recombinant therapeutic proteins: production platforms and challenges. Biotechnol J 3 (2008) 90-97
19. Kornreich R., Desnick R.J., and Bishop D.F. Nucleotide sequence of the human alpha-galactosidase A gene. Nucleic Acids Res 17 (1989) 3301-3302
20. Bernstein H.S., Bishop D.F., Astrin K.H., Kornreich R., Eng C.M., Sakuraba H., et al. Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene. J Clin Invest 83 (1989) 1390-1399
21. Ashton-Prolla P., Tong B., Shabbeer J., Astrin K.H., Eng C.M., and Desnick R.J. Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Investig Med 48 (2000) 227-235
22. Topaloglu A.K., Ashley G.A., Tong B., Shabbeer J., Astrin K.H., Eng C.M., et al. Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease. Mol Med 5 (1999) 806-811
23. Lyon M.F. Some milestones in the history of X-chromosome inactivation. Annu Rev Genet 26 (1992) 16-28
24. Laney D.A., and Fernhoff P.M. Diagnosis of Fabry disease via analysis of family history. J Genet Couns (2008 Jan 3) [Epub ahead of print]
25. Desnick R.J., and Brady R.O. Fabry disease in childhood. J Pediatr 144 (2004) 20-26
26. Altarescu G., Moore D.F., Pursley R., Campia U., Goldstein S., Bryant M., et al. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 32 (2001) 1559-1562
27. DeGraba T., Azhar S., Dignat-George F., Brown E., Boutiere B., Altarescu G., et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 47 (2000) 229-233
28. Dutsch M., Marthol H., Stemper B., Brys M., Haendl T., and Hilz M.J. Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 19 (2002) 575-586
29. Low M., Nicholls K., Tubridy N., Hand P., Velakoulis D., Kiers L., et al. Neurology of Fabry disease. Intern Med J 37 (2007) 436-447
30. Moller A.T., and Jensen T.S. Neurological manifestations in Fabry's disease. Nat Clin Pract Neurol 3 (2007) 95-106
31. Schiffmann R., and Scott L.J. Pathophysiology and assessment of neuropathic pain in Fabry disease. Acta Paediatr 91 (2002) 48-52
32. Toyooka K., and Said G. Nerve biopsy findings in hemizygous and heterozygous patients with Fabry's disease. J Neurol 244 (1997) 464-468
33. Kolodny E., and Pastores G. Anderson-Fabry disease: extrarenal, neurologic manifestations. J Am Soc Nephrol 13 (2002) 150-153
34. Lao L.M., Kumakiri M., Mima H., Kuwahara H., Ishida H., Ishiguro K., et al. The ultrastructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidrosis. J Dermatol Sci 18 (1998) 109-117
35. Tabata H., Yamakage A., and Yamazaki S. Hair abnormality of Fabry disease. Int J Dermatol 35 (1996) 576-578
36. Sheth K.J., Werlin S.L., Freeman M.E., and Hodach A.E. Gastrointestinal structure and function in Fabry's disease. Am J Gastroenterol 76 (1981) 246-251
37. Sessa A., Meroni M., Battini G., Maglio A., Brambilla P.L., Bertella M., et al. Renal pathological changes in Fabry disease. J Inherit Metab Dis 24 (2001) 66-70
38. Thurberg B.L., Rennke H., Colvin R.B., Dikman S., Gordon R.E., Collins A.B., et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62 (2002) 1933-1946
39. Kampmann C., Wiethoff C.M., Perrot A., Beck M., Dietz R., and Osterziel K.J. The heart in Anderson Fabry disease. Z Kardiol 91 (2002) 786-795
40. Linhart A., Magage S., Palecek T., and Bultas J. Cardiac involvement in Fabry disease. Acta Paediatr Suppl 91 (2002) 15-20
41. deVeber GA. Schwarting GA, Kolodny EH, Kowall NW. Fabry disease: immunocytochemical characterization of neuronal involvement. Ann Neurol 31 (1992) 409-415
42. Kaye E.M., Kolodny E.H., Logigian E.L., and Ullman M.D. Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann Neurol 23 (1988) 505-509
43. Rosenberg D.M., Ferrans V.J., Fulmer J.D., Line B.R., Barranger J.A., Brady R.O., et al. Chronic airflow obstruction in Fabry's disease. Am J Med 68 (1980) 898-905
44. Nistal M., Paniagua R., and Picazo M.L. Testicular and epididymal involvement in Fabry's disease. J Pathol 141 (1983) 113-124
45. Cole A.L., Lee P.J., Hughes D.A., Deegan P.B., Waldek S., and Lachmann R.H. Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis (2007 Nov 12) [Epub ahead of print]
46. Cable W.J., Kolodny E.H., and Adams R.D. Fabry disease: impaired autonomic function. Neurology 32 (1982) 498-502
47. Fellgiebel A., Muller M.J., and Ginsberg L. CNS manifestations of Fabry's disease. Lancet Neurol 5 (2006) 791-795
48. Mitsias P., and Levine S.R. Cerebrovascular complications of Fabry's disease. Ann Neurol 40 (1996) 8-17
49. Germain D.P., Avan P., Chassaing A., and Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet 3 (2002) 10
50. Morgan S.H., Rudge P., Smith S.J., Bronstein A.M., Kendall B.E., Holly E., et al. The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency): investigation of symptomatic and presymptomatic patients. Q J Med 75 (1990) 491-507
51. Marino S., Borsini W., Buchner S., Mortilla M., Stromillo M.L., Battaglini M., et al. Diffuse structural and metabolic brain changes in Fabry disease. J Neurol 253 (2006) 434-440
52. Keilmann A. Inner ear function in children with Fabry disease. Acta Paediatr 92 (2003) 31-32
53. Ries M., Kim H.J., Zalewski C.K., Mastroianni M.A., Moore D.F., Brady R.O., et al. Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain 130 (2007) 143-150
54. Hegemann S., Hajioff D., Conti G., Beck M., Sunder-Plassmann G., Widmer U., et al. Hearing loss in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest 36 (2006) 654-662
55. Eng C.M., Fletcher J., Wilcox W.R., Waldek S., Scott C.R., Sillence D.O., et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30 (2007) 184-192
56. Mohrenschlager M., Braun-Falco M., Ring J., and Abeck D. Fabry disease: recognition and management of cutaneous manifestations. Am J Clin Dermatol 4 (2003) 189-196
57. Schiller P.I., and Itin P.H. Angiokeratomas: an update. Dermatology 193 (1996) 275-282
58. Okubo H. Several functional and fluorescein fundus angiographic findings in Fabry's disease. Ophthalmologica 196 (1988) 132-136
59. Sodi A., Ioannidis A.S., Mehta A., Davey C., Beck M., and Pitz S. Ocular manifestations of Fabry disease: data from the Fabry Outcome Survey. Br J Ophthalmol 14 (2006) 14
60. Hauser A.C., Lorenz M., and Sunder-Plassmann G. The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy. J Intern Med 255 (2004) 629-636
61. Franceschetti A.T. Fabry disease: ocular manifestations. Birth Defects Orig Artic Ser 12 (1976) 195-208
62. Sher N.A., Letson R.D., and Desnick R.J. The ocular manifestations in Fabry's disease. Arch Ophthalmol 97 (1979) 671-676
63. Andersen M.V., Dahl H., Fledelius H., and Nielsen N.V. Central retinal artery occlusion in a patient with Fabry's disease documented by scanning laser ophthalmoscopy. Acta Ophthalmol 72 (1994) 635-638
64. Abe H., Sakai T., Sawaguchi S., Hasegawa S., Takagi M., Yoshizawa T., et al. Ischemic optic neuropathy in a female carrier with Fabry's disease. Ophthalmologica 205 (1992) 83-88
65. Meroni M., Spisni C., Tazzari S., Di Vito R., Stingone A., Bovan I., et al. Isolated glomerular proteinuria as the only clinical manifestation of Fabry's disease in an adult male. Nephrol Dial Transplant 12 (1997) 221-223
66. Branton M.H., Schiffmann R., Sabnis S.G., Murray G.J., Quirk J.M., Altarescu G., et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 81 (2002) 122-138
67. Peterson J.C., Adler S., Burkart J.M., Greene T., Hebert L.A., Hunsicker L.G., et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 15 123 (1995) 754-762
68. Ortiz A., Oliveira J.P., Waldek S., Warnock D.G., Cianciaruso B., and Wanner C. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant (2008 Jan 9) [Epub ahead of print]
69. Germain D.P., Waldek S., Banikazemi M., Bushinsky D.A., Charrow J., Desnick R.J., et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18 (2007) 1547-1557
70. Fabry RADAR 2007: The Fabry Registry Aggregate Data Annual Report.
71. Thadhani R., Wolf M., West M.L., Tonelli M., Ruthazer R., Pastores G.M., et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 61 (2002) 249-255
72. Ries M., Ramaswami U., Parini R., Lindblad B., Whybra C., Willers I., et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 162 (2003) 767-772
73. Chimenti C., Pieroni M., Morgante E., Antuzzi D., Russo A., Russo M.A., et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110 (2004) 1047-1053
74. Sachdev B., Takenaka T., Teraguchi H., Tei C., Lee P., McKenna W.J., et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105 (2002) 1407-1411
75. Pieroni M., Chimenti C., Ricci R., Sale P., Russo M.A., and Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 22 107 (2003) 1978-1984
76. Weidemann F., Breunig F., Beer M., Sandstede J., Turschner O., Voelker W., et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108 (2003) 1299-1301
77. Breunig F., Weidemann F., Strotmann J., Knoll A., and Wanner C. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69 (2006) 1216-1221
78. Linhart A., Palecek T., Bultas J., Ferguson J.J., Hrudova J., Karetova D., et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 139 (2000) 1101-1108
79. Moon J.C., Sheppard M., Reed E., Lee P., Elliott P.M., and Pennell D.J. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 8 (2006) 479-482
80. Amann-Vesti B.R., Gitzelmann G., Widmer U., Bosshard N.U., Steinmann B., and Koppensteiner R. Severe lymphatic microangiopathy in Fabry disease. Lymphat Res Biol 1 (2003) 185-189
81. Brown L.K., Miller A., Bhuptani A., Sloane M.F., Zimmerman M.I., Schilero G., et al. Pulmonary involvement in Fabry disease. Am J Respir Crit Care Med 155 (1997) 1004-1010
82. Bierer G., Kamangar N., Balfe D., Wilcox W.R., and Mosenifar Z. Cardiopulmonary exercise testing in Fabry disease. Respiration 72 (2005) 504-511
83. Magage S., Lubanda J.C., Susa Z., Bultas J., Karetova D., Dobrovolny R., et al. Natural history of the respiratory involvement in Anderson-Fabry disease. J Inherit Metab Dis 30 (2007) 790-799
84. Hoffmann B., Schwarz M., Mehta A., and Keshav S. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 5 (2007) 1447-1453
85. Manger B., Mengel E., and Schaefer R.M. Rheumatologic aspects of lysosomal storage diseases. Clin Rheumatol 26 (2007) 335-341
86. Cox-Brinkman J., Vedder A., Hollak C., Richfield L., Mehta A., Orteu K., et al. Three-dimensional face shape in Fabry disease. Eur J Hum Genet 15 (2007) 535-542
87. Ries M., Moore D.F., Robinson C.J., Tifft C.J., Rosenbaum K.N., Brady R.O., et al. Quantitative dysmorphology assessment in Fabry disease. Genet Med 8 (2006) 96-101
88. Lien Y.H., and Lai L.W. Bilateral femoral head and distal tibial osteonecrosis in a patient with Fabry disease. Am J Orthop 34 (2005) 192-194
89. Germain D.P., Benistan K., Boutouyrie P., and Mutschler C. Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. Clin Genet 68 (2005) 93-95
90. Mersebach H., Johansson J.O., Rasmussen A.K., Bengtsson B.A., Rosenberg K., Hasholt L., et al. Osteopenia: a common aspect of Fabry disease: Predictors of bone mineral density. Genet Med 9 (2007) 812-818
91. Eng C.M., Germain D.P., Banikazemi M., Warnock D.G., Wanner C., Hopkin R.J., et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8 (2006) 539-548
92. Grewal R.P. Psychiatric disorders in patients with Fabry's disease. Int J Psychiatry Med 23 (1993) 307-312
93. Sadek J., Shellhaas R., Camfield C.S., Camfield P.R., and Burley J. Psychiatric findings in four female carriers of Fabry disease. Psychiatr Genet 14 (2004) 199-201
94. Tsutsumi O., Sato M., Sato K., Mizuno M., and Sakamoto S. Early prenatal diagnosis of inborn error of metabolism: a case report of a fetus affected with Fabry's disease. Asia Oceania J Obstet Gynaecol 11 (1985) 39-45
95. Vedder A.C., Strijland A., vd Bergh Weerman M.A., Florquin S., Aerts J.M., and Hollak C.E. Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis 29 (2006) 106-111
96. Ramaswami U., Whybra C., Parini R., Pintos-Morell G., Mehta A., Sunder-Plassmann G., et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95 (2006) 86-92
97. Kint J.A. Fabry's disease: alpha-galactosidase deficiency. Science 167 (1970) 1268-1269
98. Chamoles N.A., Blanco M., and Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 308 (2001) 195-196
99. Skoog W.A., and Beck W.S. Studies on the fibrinogen, dextran and phytohemagglutinin methods of isolating leukocytes. Blood 11 (1956) 436-454
100. Coelho J.C., and Giugliani R. Fibroblasts of skin fragments as a tool for the investigation of genetic diseases: technical recommendations. Gen Mol Biol 23 (2000) 269-271
101. Desnick R.J., Brady R., Barranger J., Collins A.J., Germain D.P., Goldman M., et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138 (2003) 338-346
102. Linthorst G.E., Vedder A.C., Aerts J.M., and Hollak C.E. Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta 353 (2005) 201-203
103. Kusiak J.W., Quirk J.M., and Brady R.O. Purification and properties of the two major isozymes of alpha-galactosidase from human placenta. J Biol Chem 253 (1978) 184-190
104. Nakao S., Takenaka T., Maeda M., Kodama C., Tanaka A., Tahara M., et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333 (1995) 288-293
105. Auray-Blais C., Cyr D., Ntwari A., West M.L., Cox-Brinkman J., Bichet D.G., et al. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab (2007 Nov 16) [Epub ahead of print]
106. Desnick R.J., Bernstein H.S., Astrin K.H., and Bishop D.F. Fabry disease: molecular diagnosis of hemizygotes and heterozygotes. Enzyme 38 (1987) 54-64
107. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215
108. Eng C.M., Resnick-Silverman L.A., Niehaus D.J., Astrin K.H., and Desnick R.J. Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. Am J Hum Genet 53 (1993) 1186-1197
109. Sanger F., Nicklen S., and Coulson A.R. DNA sequencing with chain-terminating inhibitors. 1977. Biotechnology 24 (1992) 104-108
110. Hilz M.J. Evaluation of peripheral and autonomic nerve function in Fabry disease. Acta Paediatr Suppl 91 (2002) 38-42
111. Argoff C.E., Barton N.W., Brady R.O., and Ziessman H.A. Gastrointestinal symptoms and delayed gastric emptying in Fabry's disease: response to metoclopramide. Nucl Med Commun 19 (1998) 887-891
112. Kelly M.M., Leigh R., McKenzie R., Kamada D., Ramsdale E.H., and Hargreave F.E. Induced sputum examination: diagnosis of pulmonary involvement in Fabry's disease. Thorax 55 (2000) 720-721
113. Shelley E.D., Shelley W.B., and Kurczynski T.W. Painful fingers, heat intolerance, and telangiectases of the ear: easily ignored childhood signs of Fabry disease. Pediatr Dermatol 12 (1995) 215-219
114. Tahir H., Jackson L.L., and Warnock D.G. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 18 (2007) 2609-2617
115. Eng C.M., Banikazemi M., Gordon R.E., Goldman M., Phelps R., Kim L., et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68 (2001) 711-722
116. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345 (2001) 9-16
117. Ohshima T., Murray G.J., Swaim W.D., Longenecker G., Quirk J.M., Cardarelli C.O., et al. Alpha-galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A 94 (1997) 2540-2544
118. Wang A., Ioannou Y., and Zeidner K. Fabry disease: generation of a mouse model with alpha-galactosidase A. Am J Hum Genet (1996) 59
119. Ioannou Y.A., Zeidner K.M., Gordon R.E., and Desnick R.J. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 68 (2001) 14-25
120. Thurberg B.L., Randolph Byers H., Granter S.R., Phelps R.G., Gordon R.E., and O'Callaghan M. Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 122 (2004) 900-908
121. Wilcox W.R., Banikazemi M., Guffon N., Waldek S., Lee P., Linthorst G.E., et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75 (2004) 65-74
122. Banikazemi M., Bultas J., Waldek S., Wilcox W.R., Whitley C.B., McDonald M., et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146 (2007) 77-86
123. Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr, in press.
124. Hilz M.J., Brys M., Marthol H., Stemper B., and Dutsch M. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology 62 (2004) 1066-1072
125. Banikazemi M., Ullman T., and Desnick R.J. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 85 (2005) 255-259
126. Spinelli L., Pisani A., Sabbatini M., Petretta M., Andreucci M.V., Procaccini D., et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet 66 (2004) 158-165
127. Kalliokoski R.J., Kantola I., Kalliokoski K.K., Engblom E., Sundell J., Hannukainen J.C., et al. The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis 29 (2006) 112-118
128. Hollak C.E., Vedder A.C., Linthorst G.E., and Aerts J.M. Novel therapeutic targets for the treatment of Fabry disease. Expert Opin Ther Targets 11 (2007) 821-833